15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

Key Takeaways Explain This Topic AI

Intra-abdominal infections require classification into primary (monomicrobial, spontaneous bacterial peritonitis), secondary (polymicrobial enteric perforation), and tertiary (persistent nosocomial peritonitis with low-virulence multidrug-resistant pathogens).

Source control is the non-negotiable cornerstone of intra-abdominal sepsis management; following successful source control, the STOP-IT trial demonstrated that a short, fixed 4-day course of antimicrobials achieves equivalent clinical outcomes to prolonged courses.

Acute severe cholangitis (Reynolds pentad: fever, jaundice, RUQ pain, shock, altered mental status) represents an infectious emergency requiring urgent biliary decompression via ERCP or percutaneous transhepatic cholangiography within 24 hours.

Necrotizing soft tissue infections (NSTIs) present with pain out of proportion to exam and require immediate surgical exploration and radical debridement; broad-spectrum empiric therapy must include clindamycin to halt exotoxin synthesis and overcome the Eagle effect.

Acute bacterial meningitis requires urgent lumbar puncture unless specific risk factors (focal deficit, new seizure, altered consciousness, papilledema, immunocompromise, history of CNS disease) call for a pre-LP head CT; when CT is needed, blood cultures and empiric antimicrobials plus IV dexamethasone (10 mg) must be administered prior to imaging.

Last updated: October 2026

Intra-Abdominal Sepsis & Source Control

Intra-abdominal infections (IAIs) encompass a wide spectrum of pathological processes ranging from localized visceral inflammation to life-threatening generalized peritonitis and septic shock. Surviving sepsis in intra-abdominal pathology hinges on rapid diagnostic categorization, immediate resuscitation, targeted broad-spectrum antimicrobial coverage, and prompt surgical or percutaneous source control.

Classification of Peritonitis

Primary Peritonitis (Spontaneous Bacterial Peritonitis [SBP]) :

Pathogenesis : Monomicrobial infection of ascitic fluid occurring without an anatomical macroscopic breach of the gastrointestinal tract, predominantly arising in patients with end-stage liver disease and portal hypertension. Bacterial translocation from the gut lumen into mesenteric lymphatics leads to bacteremia and hematogenous seeding of ascitic fluid.

Microbiology : Enteric Gram-negative bacilli ( Escherichia coli , Klebsiella pneumoniae ) and Streptococcus species.

Diagnosis & Therapy : Diagnostic paracentesis demonstrating an ascitic fluid absolute polymorphonuclear (PMN) count ≥ 250 / μ L \ge 250/\mu\text{L} ≥ 250/ μ L (calculated as Total Nucleated Cells × % Neutrophils \text{Total Nucleated Cells} \times \%\text{Neutrophils} Total Nucleated Cells × % Neutrophils ). First-line treatment is a third-generation cephalosporin (Ceftriaxone 2 g 2\text{ g} 2 g IV q24h) plus intravenous albumin ( 1.5 g/kg 1.5\text{ g/kg} 1.5 g/kg within 6 hours of diagnosis, followed by 1.0 g/kg 1.0\text{ g/kg} 1.0 g/kg on Day 3) to prevent hepatorenal syndrome and reduce mortality.

Secondary Peritonitis :

Pathogenesis : Direct loss of gastrointestinal tract mucosal integrity leading to contamination of the sterile peritoneal cavity (perforated appendicitis, perforated diverticulitis, peptic ulcer perforation, bowel ischemia/infarction, or postoperative anastomotic dehiscence).

Microbiology : Dynamic polymicrobial synergy. Aerobic and facultative Gram-negative bacilli ( E. coli , Klebsiella , Proteus ) and Enterococci trigger early acute endotoxemia and systemic sepsis, whereas obligate anaerobes ( Bacteroides fragilis , Peptostreptococcus , Clostridium species) drive secondary fibrin deposition and intra-abdominal abscess formation.

Tertiary Peritonitis :

Pathogenesis : Persistent or recurrent intra-abdominal infection occurring > 48 hours > 48\text{ hours} > 48 hours after apparently successful surgical source control of secondary peritonitis. Characterized by ongoing systemic inflammation, multiorgan dysfunction, and failure to clear peritoneal contamination.

Microbiology : Colonization by low-virulence, opportunistic, and multidrug-resistant nosocomial pathogens: Enterococcus faecium , Candida species ( C. albicans , C. glabrata ), Pseudomonas aeruginosa , Acinetobacter baumannii , and coagulase-negative staphylococci. Treatment requires aggressive intensive care support and tailored antimicrobial regimens covering resistant Gram-negatives, resistant enterococci, and fungi.

The Primacy of Source Control

Source control represents the physical control of the infectious focus and the mitigation of ongoing microbial contamination. Common source control interventions include:

Resection or primary repair of perforated visceral organs (e.g., sigmoid colectomy with Hartmann pouch for perforated diverticulitis).

Drainage of localized fluid collections and purulent abscesses (percutaneous CT- or ultrasound-guided catheter drainage is preferred over open surgical drainage for discrete, well-defined collections).

Debridement of non-viable tissue (e.g., necrotizing pancreatitis step-up approach: initial conservative medical stabilization → \rightarrow → percutaneous catheter drainage → \rightarrow → minimally invasive video-assisted retroperitoneal debridement [VARD] or endoscopic transgastric necrosectomy).

Warning

Antimicrobial therapy without source control is universally futile. Systemic antibiotics cannot penetrate large avascular collections, cannot sterilize ischemic necrotic tissue, and cannot counteract ongoing continuous contamination from an unsealed gastrointestinal perforation.

Antimicrobial Duration: The STOP-IT Trial

Historically, clinicians continued antibiotic therapy in intra-abdominal infections until complete normalization of fever, leukocytosis, and bowel function, frequently resulting in 10- to 14-day courses. The landmark STOP-IT Trial (Study to Optimize Peritoneal Infection Therapy; Sawyer et al., NEJM 2015) randomized 518 patients with complicated intra-abdominal infections and adequate surgical or percutaneous source control to either:

Experimental Group : A short, fixed course of antimicrobial therapy for 4.0 ± 1.0 days 4.0 \pm 1.0\text{ days} 4.0 ± 1.0 days (approximately 96 hours) regardless of fever or leukocytosis.

Control Group : Traditional therapy continued until 2 days after the resolution of fever, leukocytosis, and ileus, up to a maximum of 10 days (median actual duration 8 days , versus 4 days in the short-course group).

Trial Outcomes : The incidence of composite adverse outcomes (surgical site infection, recurrent intra-abdominal infection, or death) was identical between both arms ( 21.8 % 21.8\% 21.8% in the experimental short-course group vs. 22.3 % 22.3\% 22.3% in the traditional group).

Clinical Takeaway : In patients who achieve definitive source control, a 4-day course of post-procedure antimicrobial therapy is fully sufficient. If a patient exhibits persistent fever, leukocytosis, or clinical deterioration after 4 to 7 days, the proper management is urgent repeat diagnostic imaging (contrast-enhanced CT of the abdomen and pelvis) to identify recurrent collections or failure of source control, not the reflexive, empirical escalation of broad-spectrum antibiotics.

Acute Cholangitis: Pathophysiology and Emergency Biliary Decompression

Acute cholangitis occurs when biliary outflow obstruction (choledocholithiasis, benign stricture, or malignant obstruction) increases intrabiliary intraductal pressure ( > 20 – 25 cmH 2 O > 20\text{--}25\text{ cmH}_2\text{O} > 20 – 25 cmH 2 ​ O ). High pressure breaks down the tight junctions between hepatocytes and biliary canaliculi, facilitating the rapid translocation of bacteria and endotoxins into the hepatic venous circulation, resulting in severe bacteremia and septic shock.

Clinical Presentation :

Charcot Triad : Fever, right upper quadrant abdominal pain, and jaundice (present in 50 – 70 % 50\text{--}70\% 50 – 70% of cases).

Reynolds Pentad : Charcot triad plus hypotension (shock) and altered mental status/confusion (indicates acute obstructive suppurative cholangitis, a catastrophic ICU emergency).

Emergency Management :

Resuscitation: Fluid resuscitation and immediate broad-spectrum IV antibiotics covering enteric Gram-negatives and anaerobes (e.g., Piperacillin-tazobactam or Cefepime plus Metronidazole).

Urgent Biliary Decompression within 24 Hours : Endoscopic Retrograde Cholangiopancreatography (ERCP) with biliary sphincterotomy and stent placement is the gold standard decompression technique. In patients presenting with septic shock or Reynolds pentad, decompression must be performed emergently ( < 12 – 24 hours < 12\text{--}24\text{ hours} < 12 – 24 hours ). If ERCP is unavailable or anatomically impossible (e.g., prior Roux-en-Y gastric bypass), percutaneous transhepatic cholangiography (PTC) or surgical decompression is mandatory.

Necrotizing Soft Tissue Infections (NSTI)

Necrotizing soft tissue infections (NSTIs) are aggressive, life-threatening infections characterized by extensive necrosis of the skin, subcutaneous tissue, superficial fascia, and deep muscular fascia. Mortality ranges from 20 % 20\% 20% to over 40 % 40\% 40% and correlates directly with time to initial surgical debridement.

Microbiological Classification

Type 1 (Polymicrobial, ∼ 70 – 80 % \sim 70\text{--}80\% ∼ 70 – 80% ) :

Synergistic mixture of obligate anaerobes ( Bacteroides , Peptostreptococcus , Clostridium ) and aerobic Gram-negative and Gram-positive bacilli ( E. coli , Klebsiella , Enterobacter , Staphylococcus ).

Typically develops in elderly patients, individuals with poorly controlled diabetes mellitus, peripheral vascular disease, immunosuppression, or post-surgical wounds.

Fournier Gangrene : A specific Type 1 NSTI of the perineum, perianal region, and external genitalia, typically originating from a perianal abscess, urethral stricture extravasation, or colorectal perforation.

Type 2 (Monomicrobial, ∼ 20 % \sim 20\% ∼ 20% ) :

Classically caused by Group A Streptococcus ( Streptococcus pyogenes / GAS) , alone or co-infecting with Staphylococcus aureus (particularly community-acquired MRSA carrying the Panton-Valentine leukocidin [PVL] gene).

Frequently affects younger, previously healthy, immunocompetent hosts following minor cuts, blunt contusions, insect bites, or non-penetrating muscle strain.

Highly associated with Streptococcal Toxic Shock Syndrome (STSS) .

Special Pathogens :

Vibrio vulnificus : Halophilic marine organism causing fulminant NSTI following saltwater exposure or raw oyster ingestion; classically severe in patients with liver cirrhosis and hemochromatosis.

Clostridium perfringens : Gas gangrene (clostridial myonecrosis) following major traumatic wounds, soil contamination, or crush injuries.

Clinical Presentation and Diagnostic Pitfalls

Cardinal Early Sign : Severe pain out of proportion to superficial physical exam findings . The patient experiences agonizing local tenderness that extends well beyond the visible borders of skin erythema.

Evolution of Physical Signs : Mild localized erythema and non-pitting, "wooden"-hard edema → \rightarrow → duskiness, bronze or purplish discoloration → \rightarrow → bullae (initially serous, progressing to hemorrhagic) → \rightarrow → cutaneous anesthesia (due to thrombosis of nutrient subcutaneous microvessels and infarction of superficial cutaneous nerves) → \rightarrow → skin breakdown, frank gangrene, and crepitus.

Crepitus : Indicates soft tissue gas production. Present in 30 – 50 % 30\text{--}50\% 30 – 50% of Type 1 polymicrobial and clostridial infections, but absent in pure Type 2 Group A Streptococcal NSTI. The absence of subcutaneous gas or crepitus never excludes necrotizing fasciitis.

The LRINEC Score and Its Limitations

The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score incorporates 6 laboratory parameters: C-reactive protein (CRP ≥ 150 mg/L \ge 150\text{ mg/L} ≥ 150 mg/L ), total white blood cell count, hemoglobin, serum sodium ( < 135 mEq/L < 135\text{ mEq/L} < 135 mEq/L ), serum creatinine ( > 1.6 mg/dL > 1.6\text{ mg/dL} > 1.6 mg/dL ), and glucose ( > 180 mg/dL > 180\text{ mg/dL} > 180 mg/dL ).

Score ≥ 6 \ge 6 ≥ 6 raises suspicion; score ≥ 8 \ge 8 ≥ 8 correlates with high probability.

Warning

Never rely on the LRINEC score or imaging to rule out NSTI. Systematic reviews demonstrate that the LRINEC score has modest sensitivity ( 60 – 80 % 60\text{--}80\% 60 – 80% ) and poor negative predictive value. A patient with fulminant Group A Streptococcal necrotizing fasciitis can present with a LRINEC score < 6 < 6 < 6 . In a critically ill patient with severe local pain, hemodynamic instability, or toxic appearance, emergent surgical exploration must NEVER be delayed to obtain MRI, CT imaging, or blood work.

Necrotizing Soft Tissue Infection vs. Cellulitis

Clinical / Diagnostic Feature Simple Non-Necrotizing Cellulitis Necrotizing Soft Tissue Infection (NSTI)

Pain Intensity Mild to moderate tenderness localized to erythema Severe, excruciating pain out of proportion to visible exam

Tissue Induration Soft, pitting, warm edema Firm, wooden-hard subcutaneous induration extending beyond erythema

Skin Changes Bright red, blanches, distinct margins Violaceous dusky hue, hemorrhagic bullae, cutaneous anesthesia, gangrene

Subcutaneous Gas Absent Present on exam (crepitus) or imaging in 30 – 50 % 30\text{--}50\% 30 – 50% (Type 1)

Systemic Hemodynamics Usually stable; low-grade fever Marked systemic toxicity, refractory septic shock, multi-organ failure

Bedside Finger Test Normal resistance; bleeding dermal planes Absence of bleeding, effortless blunt fascial dissection, turbid "dishwater" fluid

• Definitive Management Medical antimicrobials alone Emergent surgical exploration and wide radical debridement
• Surgical and Medical Management of NSTI

Emergent Surgical Debridement : Definitive diagnosis and cure require operative exploration. A bedside "finger test" (a small 2 -cm 2\text{-cm} 2 -cm incision under local anesthesia along the deep fascia) confirms the diagnosis if the surgeon encounters no tissue resistance to blunt finger dissection, lack of bleeding along thrombosed fascial planes, and presence of thin, malodorous, grayish exudate ("dishwater pus"). Radical excision of all necrotic, non-bleeding fascia and muscle must be performed immediately, followed by scheduled "second-look" re-explorations every 24 hours until tissue viability is secured.

Antimicrobial Regimen :

Broad-spectrum Gram-positive and MRSA coverage: Vancomycin ( 15 – 20 mg/kg 15\text{--}20\text{ mg/kg} 15 – 20 mg/kg IV q8-12h) or Daptomycin ( 8 – 10 mg/kg 8\text{--}10\text{ mg/kg} 8 – 10 mg/kg IV q24h).

PLUS Broad-spectrum Gram-negative and anaerobic coverage: Piperacillin-Tazobactam ( 4.5 g 4.5\text{ g} 4.5 g IV q6h) OR Meropenem ( 1 g 1\text{ g} 1 g IV q8h).

PLUS Clindamycin ( 600 – 900 mg 600\text{--}900\text{ mg} 600 – 900 mg IV every 8 hours).

The Eagle Effect and Clindamycin Mechanism

The Eagle Effect : Beta-lactam antibiotics (penicillins and cephalosporins) exert their bactericidal effect by binding to penicillin-binding proteins (PBPs) during active bacterial cell wall synthesis. In high-inoculum, deep-tissue infections, bacteria enter the stationary growth phase, markedly downregulating PBP expression. Consequently, penicillin and beta-lactam bactericidal efficacy drops dramatically in advanced necrotizing fasciitis.

Clindamycin Toxin Suppression : Clindamycin functions as a protein synthesis inhibitor by reversibly binding to the 50S ribosomal subunit . Its efficacy is entirely independent of bacterial growth phase or inoculum size. Clindamycin rapidly shuts down the transcription and ribosomal synthesis of streptococcal pyrogenic exotoxins (SpeA, SpeB, SpeC), streptolysin O, and clostridial alpha-toxin, arresting cytokine storm, vasoplegic shock, and capillary leak syndrome.

Intravenous Immunoglobulin (IVIG) : Dosed at 1 g/kg 1\text{ g/kg} 1 g/kg on Day 1, followed by 0.5 g/kg 0.5\text{ g/kg} 0.5 g/kg on Days 2 and 3. Indicated as an adjunctive therapy in severe Streptococcal Toxic Shock Syndrome (STSS) associated with NSTI to neutralize circulating streptococcal superantigens.

Central Nervous System Infections: Acute Bacterial Meningitis

Acute bacterial meningitis is a life-threatening neuro-infectious emergency requiring immediate diagnostic risk stratification and urgent empiric therapy. Cortical inflammation, cerebral edema, elevated intracranial pressure (ICP), and ischemic strokes account for high acute mortality ( 15 – 25 % 15\text{--}25\% 15 – 25% ) and persistent neurological morbidity (sensorineural hearing loss, seizures, cognitive deficits).

Pathogen Spectrum by Host Demographics

Streptococcus pneumoniae : The most common overall pathogen across all adult age groups, accounting for > 50 % > 50\% > 50% of adult bacterial meningitis cases. Associated with contiguous spread (otitis media, mastoiditis, sinusitis), basilar skull fractures with CSF leak, asplenia, and highest mortality.

Neisseria meningitidis : Young adults, military personnel, and college students. Rapid progression with distinctive petechial and purpuric cutaneous lesions (purpura fulminans). May precipitate bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome).

Listeria monocytogenes : Adults aged > 50 years > 50\text{ years} > 50 years , pregnant women, alcoholics, solid organ transplant recipients, and individuals with hematologic malignancies or receiving immunosuppressive therapy (corticosteroids, TNF inhibitors). Listeria is intrinsically resistant to all cephalosporins due to low binding affinity to its penicillin-binding proteins.

Diagnostic Approach & Indications for Pre-LP Neuroimaging

Definitive diagnosis requires a lumbar puncture (LP) to assess opening pressure, cerebrospinal fluid (CSF) cell count with differential, CSF glucose, protein, Gram stain, and multiplex PCR. However, performing an LP in a patient with a cerebral mass lesion or significant brain shift carries a theoretical risk of precipitating fatal uncal or transtentorial brain herniation.

Specific Indications for Head CT PRIOR to Lumbar Puncture (IDSA Guidelines):

Focal neurological deficits (e.g., hemiparesis, visual field cut, facial asymmetry; excludes isolated cranial nerve VI or VII palsies).

New-onset seizure within the preceding 1 week.

Abnormal level of consciousness (the 2016 ESCMID guideline uses a GCS score < 10 < 10 < 10 as its threshold).

Papilledema on fundoscopic examination (indicates elevated ICP).

Immunocompromised host (HIV/AIDS, immunosuppressive medications, post-transplantation).

History of central nervous system disease (mass lesion, stroke, or focal infection). SUSPECTED BACTERIAL MENINGITIS

• │
• ┌─────────────────────┴─────────────────────┐
• ▼ ▼

Pre-LP Head CT Criteria Present? No CT Criteria Present:

• Focal neurologic deficit - Normal sensorium
• New seizure within 1 week - No focal neurological signs
• Severely depressed GCS (<10) - No papilledema
• Papilledema - Immunocompetent
• Immunocompromised state or prior CNS disease │
• │ ▼
• │ YES IMMEDIATE LUMBAR PUNCTURE
• ▼ Followed immediately by
• 1. DRAW BLOOD CULTURES Dexamethasone + Antibiotics

2. ADMINISTER IMMEDIATELY:

• IV Dexamethasone (10 mg)
• Empiric Antibiotics
• 3. PERFORM NON-CONTRAST HEAD CT
• 4. PERFORM LUMBAR PUNCTURE (if no shift)

Important

The Golden Rule of Meningitis Timing : If a patient requires a non-contrast head CT prior to lumbar puncture, the clinician must draw blood cultures and IMMEDIATELY administer empiric antimicrobial therapy plus IV dexamethasone BEFORE transporting the patient to the CT scanner . Under no circumstances should antimicrobial administration be delayed for imaging. Delaying antibiotic administration by > 2 hours > 2\text{ hours} > 2 hours in acute bacterial meningitis is directly linked to increased in-hospital mortality.

Empiric Antimicrobial Regimens & Dexamethasone Protocols

Patient Population Recommended Empiric Antimicrobial Regimen Key Clinical Pearls

Adults aged 18 to 49 years Ceftriaxone 2 g 2\text{ g} 2 g IV q12h (or Cefotaxime 2 g 2\text{ g} 2 g IV q4h) PLUS Vancomycin 15 – 20 mg/kg 15\text{--}20\text{ mg/kg} 15 – 20 mg/kg IV q8-12h (target trough 15 – 20 mcg/mL 15\text{--}20\text{ mcg/mL} 15 – 20 mcg/mL ) High-dose ceftriaxone provides bactericidal CSF concentrations against S. pneumoniae and N. meningitidis . Vancomycin is added to cover cephalosporin-resistant S. pneumoniae .

Adults aged ≥ 50 \ge 50 ≥ 50 years OR Immunocompromised Ceftriaxone 2 g 2\text{ g} 2 g IV q12h PLUS Vancomycin 15 – 20 mg/kg 15\text{--}20\text{ mg/kg} 15 – 20 mg/kg IV q8-12h PLUS Ampicillin 2 g 2\text{ g} 2 g IV q4h Ampicillin is mandatory to cover Listeria monocytogenes , which is intrinsically resistant to all cephalosporins.

Severe β \beta β -Lactam Anaphylaxis Vancomycin 15 – 20 mg/kg 15\text{--}20\text{ mg/kg} 15 – 20 mg/kg IV q8-12h PLUS Moxifloxacin 400 mg 400\text{ mg} 400 mg IV q24h PLUS Trimethoprim-Sulfamethoxazole ( 5 mg/kg 5\text{ mg/kg} 5 mg/kg TMP IV q8h, if Listeria risk present) Moxifloxacin crosses the blood-brain barrier; TMP-SMX provides alternative Listeria coverage.

Adjunctive Dexamethasone Protocol

Dosing and Administration : Dexamethasone 10 mg 10\text{ mg} 10 mg IV administered 15 to 20 minutes BEFORE, or at the latest CONCURRENTLY WITH, the first dose of antimicrobial therapy , continued at 10 mg 10\text{ mg} 10 mg IV every 6 hours for 4 days .

Pathophysiological Rationale : Antibiotic-mediated lysis of bacteria releases large amounts of cell wall components (peptidoglycans, teichoic acid, lipopolysaccharide, and pneumolysin) into the subarachnoid space, triggering an intense burst of meningeal neuroinflammation, cerebral edema, elevated intracranial pressure, and neuronal apoptosis. Administering corticosteroids prior to bacteriolysis downregulates pro-inflammatory cytokine expression (TNF- α \alpha α , IL-1 β \beta β ).

Clinical Evidence : The European Dexamethasone Study (de Gans and van de Beek, NEJM 2002) established that early adjunctive dexamethasone reduces 8-week mortality ( 7 % 7\% 7% vs. 15 % 15\% 15% ) and unfavorable neurological outcomes—particularly severe sensorineural hearing loss—in adults with Streptococcus pneumoniae meningitis.

De-escalation Rule : IDSA advises continuing dexamethasone only when Streptococcus pneumoniae is confirmed and stopping it for other causes; the 2016 ESCMID guideline continues it for S. pneumoniae or Haemophilus influenzae and stops it when bacterial meningitis is excluded or another organism (for example Listeria ) is identified.